Cordlife to buy cord blood bank HealthBaby
Add BT as a preferred sourceSingapore
IN a bid to expand its presence in Hong Kong and Macau, Singapore-listed consumer healthcare company Cordlife Group has signed an agreement to buy out private cord blood bank HealthBaby Biotech (Hong Kong) Co from Stemgen Biotech Holding.
As part of the transaction, Cordlife will assume the debt of HK$138.2 million (S$23.8 million) which Stemgen Biotech Holding owed to HealthBaby Hong Kong.
TRENDING NOW
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
MSCI drops S-E Asian heavyweights Sembcorp, GoTo and Ayala Land from global benchmarks
